头孢他啶/阿维巴坦治疗药物监测研究进展  

Research progress in therapeutic drug monitoring of ceftazidime/avibactam

作　　者：刘潇阳 李博 陈玥 李朋梅[1] LIU Xiao-yang;LI Bo;CHEN Yue;LI Peng-mei(Department of Pharmacy,China-Japan Friendship Hospital,Beijing 100029,China;Department of Pharmacy Administration and Clinical Pharmacy Shool of Pharmaceutical Sciences,Peking University,Beijing 100191,China)

机构地区：[1]中日友好医院药学部,北京100029 [2]北京大学药学院临床药学与药事管理学系,北京100191

出　　处：《中国新药杂志》2024年第9期904-910,共7页Chinese Journal of New Drugs

基　　金：北京药学会临床药学研究课题项目(LCYX-2022-07)。

摘　　要：头孢他啶/阿维巴坦(CAZ/AVI)是一种新型头孢菌素/β-内酰胺酶抑制剂复合制剂,为了在不同类型的患者中达到更好的疗效,降低耐药风险和不良反应发生率,临床上常采用治疗药物监测(therapeutic drug monitoring, TDM)来监测CAZ/AVI的体内药物浓度。本文基于近年来国内外的相关文献,对CAZ/AVI实施TDM的意义、目前的TDM方法、药动学/药效学监测指标以及在特殊人群中实施TDM的现状进行了综述,以期为CAZ/AVI的个体化治疗提供建议。Ceftazidime/avibactam(CAZ/AVI)is a new type of cephalosporin/β-lactamase inhibitor compound preparation.In order to achieve better treatment results in different types of patients and reduce the risk of drug resistance and incidence of adverse reactions,therapeutic drug monitoring(TDM)is often used clinically to monitor the concentration of CAZ/AVI in vivo.This article reviews the significance of implementing TDM for CAZ/AVI,current TDM methods,PK/PD monitoring indicators,and the current status of implementing TDM in special populations,to provide a basis for the individualization of CAZ/AVI treatment.

关 键 词：头孢他啶/阿维巴坦 治疗药物监测 药动学/药效学靶标 特殊人群用药 β-内酰胺/β内酰胺酶抑制剂 

分 类 号：R961[医药卫生—药理学]